What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

What question did this study set out to answer?

To investigate the effects of Eculizumab on hyperhemolysis syndrome outcomes in sickle cell disease.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Systematic review shows Eculizumab resolves hyperhemolysis syndrome in sickle cell disease patients, suggesting improved survival rates.

To investigate the effects of Eculizumab on hyperhemolysis syndrome outcomes in sickle cell disease.
Conducted a systematic review following PRISMA guidelines.
Performed a comprehensive literature search across various databases.
Included 11 original studies reporting outcomes in patients treated with Eculizumab.
Eculizumab resulted in a 93% resolution rate of hyperhemolysis syndrome.
The pooled overall survival rate was 93% at last follow-up.
Low rates of recurrence (0%) and mortality (7%) were observed.

Moazzam Shahzad (2025) studied this question.

View Full Paper

Ask AI

Bookmark